Jody A. Charnow

Complete response to induction therapy is associated with significant 82% decreased odds of death at 12 months.

Using electrochemiluminescence, researchers found 5 urinary proteins that have “reasonable specificity” for lupus nephritis.

Gout may be a risk factor for the development of CKD stage ≥3.

An expert panel evaluated 23 separate statements related to the etiology, diagnosis, and treatment of gout.

Study reveals an 11% prevalence of active gout among solid organ transplant recipients overall and a 13% prevalence among kidney transplant recipients.

Patients with gout who did not reach a serum uric acid level below 6 mg/dL had a 2.4-fold increased risk for death.

In a British study, nurse-led care emphasizing patient education and engagement significantly improved the proportion of gout sufferers who achieved target serum urate levels.

Inhibition of IL-1ß with canakinumab significantly decreased gout attack risk at all baseline serum uric acid (SUA) levels and without changing SUA levels.

Over a 5-year period, the drug was well tolerated and associated with significant declines in urinary protein-creatinine ratio and mean prednisolone dose.

The 10-year prevalence of colonoscopy-documented colorectal cancer was 0.8% among gout patients vs 3.7% among osteoarthritis patients.

In a large Swedish study of middle-aged individuals, increments in baseline serum urate levels were associated with progressively increased risks of gout over a mean 28 years of follow-up.

A study of Medicare patients found that atrial fibrillation was nearly twice as likely to develop in those with vs without gout.

A study documents a 27% increase in visits to emergency departments for a primary diagnosis of acute gout from 2006 to 2014.